Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method

Cancer

Volumn 117, Issue 7, 2011, Pages 1386-1398

  Pinchot, Scott N ^a   Jaskula Sztul, Renata ^a   Ning, Li ^a   Peters, Noel R ^a   Cook, MacKenzie R ^a   Kunnimalaiyaan, Muthusamy ^a   Chen, Herbert ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

achaete scute complex like 1; carcinoid; neuroendocrine; resveratrol

Indexed keywords

CHROMOGRANIN A; CYCLIN DEPENDENT KINASE 2; ISOPROTEIN; LUCIFERASE; NOTCH RECEPTOR; NOTCH2 RECEPTOR; RESVERATROL; SEROTONIN; TRANSCRIPTION FACTOR MASH1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BINDING SITE; CANCER INHIBITION; CARCINOID; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; ENDOCRINE DISEASE; HIGH THROUGHPUT SCREENING; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REPORTER GENE; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH; UPREGULATION; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; STILBENES; UP-REGULATION;

EID: 79952856783     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25652     Document Type: Article

References (57)

1. Kadesch T., Notch signaling: the demise of elegant simplicity. Curr Opin Genet Dev. 2004; 14: 506-512. (Pubitemid 39360297)
2. Maillard I, Pear W., Notch and cancer: best to avoid the ups and downs. Cancer Cell. 2003; 3: 203-205. (Pubitemid 37443875)
3. Yoon K, Gaiano N., Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci. 2005; 8: 709-715. (Pubitemid 43085834)
4. Allenspach E, Maillard I, Aster J, Pear W., Notch signaling in cancer. Cancer Biol Ther. 2002; 1: 466-476.
5. Artavanis-Tsakonas S, Rand M, Lake R., Notch signaling: cell fate control and signal integration in development. Science. 1999; 284: 770-776. (Pubitemid 29291335)
6. Cabrera C., Lateral inhibition and cell fate during neurogenesis in Drosophila: the interactions between scute, Notch and Delta. Development. 1990; 110: 733-742.
7. Cabrera C., The generation of cell diversity during early neurogenesis in Drosophila. Development. 1992; 115: 893-901.
8. Ellisen L, Bird J, West D, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991; 66: 649-661. (Pubitemid 121001701)
9. Yamaguchi N, Oyama T, Ito E, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res. 2008; 68: 1881-1888. (Pubitemid 351416574)
10. Hao L, Rizzo P, Osipo C, et al. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene. 2010; 29: 201-213.
11. Liu Z, Xiao M, Balint K, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 2006; 66: 4182-4190.
12. Dang T, Eichenberger S, Gonzalez A, Olson S, Carbone D., Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene. 2003; 22: 1988-1997. (Pubitemid 36523636)
13. Jeffries S, Capobianco A., Neoplastic transformation by Notch requires nuclear localization. Mol Cell Biol. 2000; 20: 3928-3241.
14. Dumont E, Fuchs K, Bommer G, Christoph B, Kremmer E, Kempkes B., Neoplastic transformation by Notch is independent of transcriptional activation by RBP-J signalling. Oncogene. 2000; 19: 556-561. (Pubitemid 30099369)
15. Okuyama R, Ogawa E, Nagoshi H, et al. p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity. Oncogene. 2007; 26: 4478-4488. (Pubitemid 47037037)
16. Demehri S, Turkoz A, Kopan R., Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell. 2009; 16: 55-66.
17. Devgan V, Mammucari C, Millar S, Brisken C, Dotto G., p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev. 2005; 19: 1485-1495. (Pubitemid 41003015)
18. Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001; 20: 3427-3436. (Pubitemid 32634350)
19. Kunnimalaiyaan M, Traeger K, Chen H., Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2005; 289: G636-G642. (Pubitemid 41377169)
20. Kunnimalaiyaan M, Vaccaro A, Ndiaye M, Chen H., Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem. 2006; 281: 39819-39830. (Pubitemid 46041785)
21. Nakakura E, Sriuranpong V, Kunnimalaiyaan M, et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab. 2005; 90: 4350-4356. (Pubitemid 41058218)
22. Sriuranpong V, Borges M, Strock C, et al. Notch signaling induces rapid degradation of achaete-scute homolog 1. Mol Cell Biol. 2002; 22: 3129-3139. (Pubitemid 34437471)
23. Greenblatt D, Vaccaro A, Jaskula-Sztul R, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist. 2007; 12: 942-951. (Pubitemid 47359136)
24. Ning L, Greenblatt D, Kunnimalaiyaan M, Chen H., Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist. 2008; 13: 98-104. (Pubitemid 351342572)
25. Ito T, Udaka N, Yazawa T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development. 2000; 127: 3913-3921.
26. Borges M, Linnoila R, van de Velde H, et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997; 386: 852-855. (Pubitemid 27181261)
27. Kunnimalaiyaan M, Chen H., Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist. 2007; 12: 535-542. (Pubitemid 350012116)
28. Sriuranpong V, Borges M, Ravi R, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001; 61: 3200-3205. (Pubitemid 32691976)
29. Tyagi A, Singh R, Agarwal C, Siriwardana S, Sclafani R, Agarwal R., Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis. 2005; 26: 1978-1987. (Pubitemid 41631273)
30. Raj M, Abd Elmageed Z, Zhou J, et al. Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol. 2008; 110: 432-438.
31. Hudson T, Hartle D, Hursting S, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res. 2007; 67: 8396-8405. (Pubitemid 47395179)
32. Aardal S, Helle K., The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept. 1992; 41: 9-18.
33. Konecki D, Benedum U, Gerdes H, Huttner W., The primary structure of human chromogranin A and pancreastatin. J Biol Chem. 1987; 262: 17026-17030. (Pubitemid 18017665)
34. Tamamura H, Ohta M, Yoshizawa K, et al. Isolation and characterization of a tumor-derived human protein related to chromogranin A and its in vitro conversion to human pancreastatin-48. Eur J Biochem. 1990; 191: 33-39. (Pubitemid 20219027)
35. Ishizuka J, Beauchamp R, Townsend CJ, Greeley GJ, Thompson J., Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol. 1992; 150: 1-7.
36. Bishayee A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila). 2009; 2: 409-418.
37. Fang N, Casida J., Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc Natl Acad Sci USA. 1998; 95: 3380-3384. (Pubitemid 28173136)
38. Zheng J, Ramirez V., Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol. 2000; 130: 1115-1123. (Pubitemid 30453547)
39. Gledhill J, Walker J., Inhibition sites in F1-ATPase from bovine heart mitochondria. Biochem J. 2005; 386: 591-598. (Pubitemid 40445885)
40. Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003; 102: 987-995. (Pubitemid 36917794)
41. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007; 109: 2293-2302. (Pubitemid 46425866)
42. Lee J, Safe S., Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol. 2001; 62: 1113-1124. (Pubitemid 32971677)
43. Lin J, Lin V, Rau K, et al. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem. 2010; 58: 1584-1592.
44. Garvin S, Ollinger K, Dabrosin C., Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006; 231: 113-122. (Pubitemid 41779459)
45. Cao Z, Fang J, Xia C, Shi X, Jiang B., trans-3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res. 2004; 10: 5253-5263. (Pubitemid 39099800)
46. Zhang Q, Tang X, Lu Q, Zhang Z, Brown J, Le A., Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther. 2005; 4: 1465-1474. (Pubitemid 41556428)
47. Musunuru S, Carpenter J, Sippel R, Kunnimalaiyaan M, Chen H., A mouse model of carcinoid syndrome and heart disease. J Surg Res. 2005; 126: 102-105. (Pubitemid 40726253)
48. Pinchot S, Pitt S, Sippel R, Kunnimalaiyaan M, Chen H., Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. Curr Opin Investig Drugs. 2008; 9: 576-582. (Pubitemid 351777161)
49. Sippel R, Chen H., Carcinoid tumors. Surg Oncol Clin N Am. 2006; 15: 463-478. (Pubitemid 44119207)
50. Kulke M, Mayer R., Carcinoid tumors. N Engl J Med. 1999; 340: 858-868. (Pubitemid 29142631)
51. Chen H, Thiagalingam A, Chopra H, et al. Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci USA. 1997; 94: 5355-5360. (Pubitemid 27214787)
52. Trincheri N, Nicotra G, Follo C, Castino R, Isidoro C., Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis. 2007; 28: 922-931. (Pubitemid 47072174)
53. Whyte L, Huang Y, Torres K, Mehta R., Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res. 2007; 67: 12007-12017.
54. Boocock D, Faust G, Patel K, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1246-1252. (Pubitemid 46984966)
55. Denu J., The Sir 2 family of protein deacetylases. Curr Opin Chem Biol 2005; 9: 431-40.
56. Prozorovski T, Schulze-Topphoff U, Glumm R, et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol. 2008; 10: 385-394.
57. Shoemaker R., The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6: 813-823. (Pubitemid 44450469)